Methamphetamine Induced Cardiomyopathy

Younes I¹, Elkattawy S^1*, Noori M¹, Posimreddy S²

¹Department of Internal Medicine, Trinitas Regional Medical Center, Elizabeth, New Jersey, USA

²Department of Cardiology, Saint Joseph’s University Medical Center, Paterson, New Jersey, USA

Corresponding Author: Sherif Elkattawy

Address: 225 Williamson Street, Elizabeth, NJ 07202, USA; Tel: 201-707-1394; Email: sherifelkattawy@gmail.com

Received date: 05 May 2020; Accepted date: 21 May 2020; Published date: 02 June 2020

Citation: Younes I, Elkattawy S, Noori M, Posimreddy S. Methamphetamine Induced Cardiomyopathy. J Health Care and Research. 2020 Jun 2;1(2):78-82.

Copyright © 2020 Younes I, Elkattawy S, Noori M, Posimreddy S. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Keywords: Methamphetamine, Cardiomyopathy, Pulmonary Artery Hypertension, Hypertension, Heart Failure

Abstract

Unfortunately, 35 million people worldwide suffer from drug use disorder while only one in seven people receive treatment. The health impacts combined with the socioeconomic burden of drug abuse are too numerous to count. It is well known that all organ systems are adversely affected by drug use including but not limited to the cardiovascular, respiratory, neurological, and renal. We will focus our attention on the effects of Methamphetamines on the cardiovascular system. Methamphetamines are known to be highly addictive stimulants with significant cardiovascular implications. We have gathered information from the literature available on methamphetamine-associated cardiomyopathy (MACM) and will discuss a case of a 58-year-old male, with no past medical history, who presented with dyspnea secondary to MACM.

Full-Text HTML